Autoimmune Hepatitis and Liver Transplantation: Indications, Results, and Management of Recurrent Disease

ABSTRACT

For those with autoimmune hepatitis (AIH), indications for liver transplantation include end-stage liver failure (as suggested by a MELD score >16), the onset of liver cancer, intractable symptoms that make the patient's life intolerable, and fulminant liver failure; outcomes are excellent, with 10-year survival in excess of 70%. For those with a fulminant presentation, the impact of corticosteroids is controversial and liver transplantation may be required. Autoimmune hepatitis recurs in approximately one third and may be detected up to 10 years or more post-transplant. There are no agreed-on criteria for the diagnosis, and differentiation from rejection and other causes of graft damage can be difficult. There is no strong correlation between the prevalence of recurrent AIH (rAIH) and graft loss from rAIH. Treatment of recurrent disease with the addition or increase in corticosteroids is often successful, although long-term data are lacking and some may progress to graft failure despite increased treatment. There remains controversy over the role for protocol liver biopsies to detect recurrent disease and the best immunosuppressive strategies to prevent and treat recurrence.

Autoimmune hepatitis - liver transplantation - recurrence - de novo autoimmune hepatitis

REFERENCES

• 1 Verslype C, George C, Buchel E, Nevens F, van Steenbergen W, Fevery J. Diagnosis and treatment of autoimmune hepatitis at age 65 and older.  Aliment Pharmacol Ther. 2005;  21(6) 695-699
• 2 Alvarez F, Berg P A, Bianchi F B et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol. 1999;  31(5) 929-938
• 3 Johnson P J, McFarlane I G. Meeting report: International Autoimmune Hepatitis Group.  Hepatology. 1993;  18(4) 998-1005
• 4 Hennes E M, Zeniya M, Czaja A J International Autoimmune Hepatitis Group et al. Simplified criteria for the diagnosis of autoimmune hepatitis.  Hepatology. 2008;  48(1) 169-176
• 5 Czaja A J, Bianchi F B, Carpenter H A et al.. Treatment challenges and investigational opportunities in autoimmune hepatitis.  Hepatology. 2005;  41(1) 207-215
• 6 Czaja A J, Carpenter H A. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis.  Dig Dis Sci. 2006;  51(5) 968-975
• 7 Heneghan M A, Allan M L, Bornstein J D, Muir A J, Tendler D A. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis.  J Hepatol. 2006;  45(4) 584-591
• 8 Alvarez F, Ciocca M, Cañero-Velasco C et al.. Short-term cyclosporine induces a remission of autoimmune hepatitis in children.  J Hepatol. 1999;  30(2) 222-227
• 9 Cuarterolo M, Ciocca M, Velasco C C et al.. Follow-up of children with autoimmune hepatitis treated with cyclosporine.  J Pediatr Gastroenterol Nutr. 2006;  43(5) 635-639
• 10 Richardson P D, James P D, Ryder S D. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.  J Hepatol. 2000;  33(3) 371-375
• 11 Hennes E M, Oo Y H, Schramm C et al.. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?.  Am J Gastroenterol. 2008;  103(12) 3063-3070
• 12 Kanzler S, Gerken G, Dienes H P, Meyer zum Büschenfelde K H, Lohse A W. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis—report of three cases.  Z Gastroenterol. 1997;  35(7) 571-578
• 13 Rowe I A, Webb K, Gunson B K, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience.  Transpl Int. 2008;  21(5) 459-465
• 14 Kamath P S, Wiesner R H, Malinchoc M et al.. A model to predict survival in patients with end-stage liver disease.  Hepatology. 2001;  33(2) 464-470
• 15 Malinchoc M, Kamath P S, Gordon F D, Peine C J, Rank J, ter Borg P C. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.  Hepatology. 2000;  31(4) 864-871
• 16 Neuberger J, Gimson A, Davies M Liver Advisory Group et al. Selection of patients for liver transplantation and allocation of donated livers in the UK.  Gut. 2008;  57(2) 252-257
• 17 Cheng A L, Kang Y K, Chen Z et al.. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.  Lancet Oncol. 2009;  10(1) 25-34
• 18 Llovet J M, Ricci S, Mazzaferro V SHARP Investigators Study Group et al. Sorafenib in advanced hepatocellular carcinoma.  N Engl J Med. 2008;  359(4) 378-390
• 19 Polak W G, Soyama A, Slooff M J. Liver transplantation in patients with hepatocellular carcinoma.  Ann Transplant. 2008;  13(4) 5-15
• 20 Mazzaferro V, Regalia E, Doci R et al.. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.  N Engl J Med. 1996;  334(11) 693-699
• 21 Yao F Y, Kerlan Jr R K, Hirose R et al.. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.  Hepatology. 2008;  48(3) 819-827
• 22 Mazzaferro V, Llovet J M, Miceli R Metroticket Investigator Study Group et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.  Lancet Oncol. 2009;  10(1) 35-43
• 23 Toso C, Meeberg G A, Bigam D L et al.. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.  Transplantation. 2007;  83(9) 1162-1168
• 24 O'Grady J G, Alexander G J, Hayllar K M, Williams R. Early indicators of prognosis in fulminant hepatic failure.  Gastroenterology. 1989;  97(2) 439-445
• 25 Ichai P, Duclos-Vallée J C, Guettier C et al.. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.  Liver Transpl. 2007;  13(7) 996-1003
• 26 Amontree J S, Stuart T D, Bredfeldt J E. Autoimmune chronic active hepatitis masquerading as acute hepatitis.  J Clin Gastroenterol. 1989;  11(3) 303-307
• 27 Bosch J, Coll M, Puig A et al.. Autoimmune hepatitis with fatal outcome.  J Pediatr. 1991;  118(5) 823-824
• 28 Ferrari R, Pappas G, Agostinelli D et al.. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the ‘acute’ type.  QJM. 2004;  97(7) 407-412
• 29 Herzog D, Rasquin-Weber A M, Debray D, Alvarez F. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation.  J Hepatol. 1997;  27(3) 578-582
• 30 Kessler W R, Cummings O W, Eckert G, Chalasani N, Lumeng L, Kwo P Y. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis.  Clin Gastroenterol Hepatol. 2004;  2(7) 625-631
• 31 Maggiore G, Porta G, Bernard O et al.. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children.  J Pediatr. 1990;  116(2) 280-282
• 32 Nikias G A, Batts K P, Czaja A J. The nature and prognostic implications of autoimmune hepatitis with an acute presentation.  J Hepatol. 1994;  21(5) 866-871
• 33 Okano N, Yamamoto K, Sakaguchi K et al.. Clinicopathological features of acute-onset autoimmune hepatitis.  Hepatol Res. 2003;  25(3) 263-270
• 34 Viruet E J, Torres E A. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis.  P R Health Sci J. 1998;  17(3) 297-300
• 35 Villamil A G, Casciato P, Eduardo M et al.. Fulminant autoimmune hepatitis: Clinical presentation, outcome and prognostic factors.  Am J Transplant. 2005;  5 278
• 36 Futagawa Y, Terasaki P I. An analysis of the OPTN/UNOS Liver Transplant Registry.  Clin Transpl. 2004;  315-329
• 37 Molmenti E P, Netto G J, Murray N G et al.. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients.  Liver Transpl. 2002;  8(6) 519-526
• 38 Neuberger J, Adams D H. What is the significance of acute liver allograft rejection?.  J Hepatol. 1998;  29(1) 143-150
• 39 Neuberger J, Portmann B, Calne R, Williams R. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting.  Transplantation. 1984;  37(4) 363-365
• 40 Ayata G, Gordon F D, Lewis W D et al.. Liver transplantation for autoimmune hepatitis: a long-term pathologic study.  Hepatology. 2000;  32(2) 185-192
• 41 Bahar R J, Yanni G S, Martín M G et al.. Orthotopic liver transplantation for autoimmune hepatitis and cryptogenic chronic hepatitis in children.  Transplantation. 2001;  72(5) 829-833
• 42 Birnbaum A H, Benkov K J, Pittman N S, McFarlane-Ferreira Y, Rosh J R, LeLeiko N S. Recurrence of autoimmune hepatitis in children after liver transplantation.  J Pediatr Gastroenterol Nutr. 1997;  25(1) 20-25
• 43 Campsen J, Zimmerman M A, Trotter J F et al.. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal.  Liver Transpl. 2008;  14(9) 1281-1286
• 44 Duclos-Vallée J C, Sebagh M, Rifai K et al.. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence.  Gut. 2003;  52(6) 893-897
• 45 González-Koch A, Czaja A J, Carpenter H A et al.. Recurrent autoimmune hepatitis after orthotopic liver transplantation.  Liver Transpl. 2001;  7(4) 302-310
• 46 Heffron T G, Smallwood G A, Oakley B et al.. Autoimmune hepatitis following liver transplantation: relationship to recurrent disease and steroid weaning.  Transplant Proc. 2002;  34(8) 3311-3312
• 47 Khalaf H, Mourad W, El-Sheikh Y et al.. Liver transplantation for autoimmune hepatitis: a single-center experience.  Transplant Proc. 2007;  39(4) 1166-1170
• 48 Milkiewicz P, Hubscher S G, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation.  Transplantation. 1999;  68(2) 253-256
• 49 Narumi S, Hakamada K, Sasaki M et al.. Liver transplantation for autoimmune hepatitis: rejection and recurrence.  Transplant Proc. 1999;  31(5) 1955-1956
• 50 Prados E, Cuervas-Mons V, de la Mata M et al.. Outcome of autoimmune hepatitis after liver transplantation.  Transplantation. 1998;  66(12) 1645-1650
• 51 Ratziu V, Samuel D, Sebagh M et al.. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease.  J Hepatol. 1999;  30(1) 131-141
• 52 Reich D J, Fiel I, Guarrera J V et al.. Liver transplantation for autoimmune hepatitis.  Hepatology. 2000;  32(4 Pt 1) 693-700
• 53 Renz J F, Ascher N L. Liver transplantation for nonviral, nonmalignant diseases: problem of recurrence.  World J Surg. 2002;  26(2) 247-256
• 54 Vogel A, Heinrich E, Bahr M J et al.. Long-term outcome of liver transplantation for autoimmune hepatitis.  Clin Transplant. 2004;  18(1) 62-69
• 55 Wright H L, Bou-Abboud C F, Hassanein T et al.. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease.  Transplantation. 1992;  53(1) 136-139
• 56 Yusoff I F, House A K, De Boer W B et al.. Disease recurrence after liver transplantation in Western Australia.  J Gastroenterol Hepatol. 2002;  17(2) 203-207
• 57 Kerkar N, Hadzić N, Davies E T et al.. De-novo autoimmune hepatitis after liver transplantation.  Lancet. 1998;  351(9100) 409-413
• 58 Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review.  Liver Transpl. 2006;  12(12) 1813-1824
• 59 Mottershead M, Neuberger J. Transplantation in autoimmune liver diseases.  World J Gastroenterol. 2008;  14(21) 3388-3395
• 60 Manns M P, Bahr M J. Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self.  Hepatology. 2000;  32(4 Pt 1) 868-870
• 61 Hübscher S G. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome.  Liver Transpl. 2001;  7(4) 285-291
• 62 Evans H M, Kelly D A, McKiernan P J, Hübscher S. Progressive histological damage in liver allografts following pediatric liver transplantation.  Hepatology. 2006;  43(5) 1109-1117
• 63 Junge G, Neuhaus R, Schewior L et al.. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis.  Transplant Proc. 2005;  37(4) 1695-1696
• 64 Uemura T, Ikegami T, Sanchez E Q et al.. Late acute rejection after liver transplantation impacts patient survival.  Clin Transplant. 2008;  22(3) 316-323
• 65 Devlin J, Donaldson P, Portmann B, Heaton N, Tan K C, Williams R. Recurrence of autoimmune hepatitis following liver transplantation.  Liver Transpl Surg. 1995;  1(3) 162-165
• 66 Milkiewicz P, Ahmed M, Hathaway M, Elias E. Factors associated with progression of the disease before transplantation in patients with autoimmune hepatitis.  Liver. 1999;  19(1) 50-54
• 67 Hurtova M, Duclos-Vallée J C, Johanet C et al.. Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient.  Liver Transpl. 2001;  7(6) 556-558
• 68 Kerkar N, Dugan C, Rumbo C et al.. Rapamycin successfully treats post-transplant autoimmune hepatitis.  Am J Transplant. 2005;  5(5) 1085-1089
• 69 Rodríguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco M C et al.. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis.  Transplant Proc. 2006;  38(5) 1467-1470
• 70 Seyam M, Neuberger J M, Gunson B K, Hübscher S G. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence.  Liver Transpl. 2007;  13(7) 966-974
• 71 Di Cocco P, Barletta A, Clemente K et al.. De novo autoimmune hepatitis following liver transplantation: a case report.  Transplant Proc. 2008;  40(6) 2073-2074
• 72 Salcedo M, Vaquero J, Bañares R et al.. Response to steroids in de novo autoimmune hepatitis after liver transplantation.  Hepatology. 2002;  35(2) 349-356
• 73 Aguilera I, Sousa J M, Gavilan F, Bernardos A, Wichmann I, Nuñez-Roldan A. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation.  Transplant Proc. 2005;  37(9) 3968-3969
• 74 Tan C K, Sian Ho J M. Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation.  Liver Transpl. 2001;  7(5) 461-465
• 75 Gao E K, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A.  Nature. 1988;  336(6195) 176-179
• 76 Czaja A J. Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance.  Liver Transpl. 2002;  8(6) 505-513
• 77 Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation.  Liver Transpl. 2004;  10(4) 488-491
• 78 Petz W, Sonzogni A, Bertani A et al.. A cause of late graft dysfunction after pediatric liver transplantation: de novo autoimmune hepatitis.  Transplant Proc. 2002;  34(5) 1958-1959
• 79 Venick R S, McDiarmid S V, Farmer D G et al.. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis.  Am J Transplant. 2007;  7(4) 955-963
• 80 D'Antiga L, Dhawan A, Portmann B et al.. Late cellular rejection in paediatric liver transplantation: aetiology and outcome.  Transplantation. 2002;  73(1) 80-84
• 81 Miyagawa-Hayashino A, Haga H, Egawa H et al.. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation.  Transplantation. 2004;  78(1) 128-135
• 82 Aguilera I, Wichmann I, Sousa J M et al.. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation.  Clin Exp Immunol. 2001;  126(3) 535-539
• 83 Gupta P, Hart J, Millis J M, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation.  Transplantation. 2001;  71(5) 664-668
• 84 Riva S, Sonzogni A, Bravi M et al.. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience.  Liver Transpl. 2006;  12(4) 573-577
• 85 Andries S, Casamayou L, Sempoux C et al.. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine.  Transplantation. 2001;  72(2) 267-272
• 86 Hernandez H M, Kovarik P, Whitington P F, Alonso E M. Autoimmune hepatitis as a late complication of liver transplantation.  J Pediatr Gastroenterol Nutr. 2001;  32(2) 131-136